146 related articles for article (PubMed ID: 31765735)
1. Oncogenic role of TYRO3 receptor tyrosine kinase in the progression of pancreatic cancer.
Morimoto M; Horikoshi Y; Nakaso K; Kurashiki T; Kitagawa Y; Hanaki T; Sakamoto T; Honjo S; Umekita Y; Fujiwara Y; Matsura T
Cancer Lett; 2020 Feb; 470():149-160. PubMed ID: 31765735
[TBL] [Abstract][Full Text] [Related]
2. Prognostic Significance of TYRO3 Receptor Tyrosine Kinase Expression in Gastric Cancer.
Uejima C; Morimoto M; Yamamoto M; Hara K; Miyauchi W; Sugezawa K; Tada Y; Tanio A; Kihara K; Matsunaga T; Tokuyasu N; Sakamoto T; Honjo S; Umekita Y; Fujiwara Y
Anticancer Res; 2020 Oct; 40(10):5593-5600. PubMed ID: 32988883
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA-7 inhibits colorectal cancer cell proliferation, migration and invasion via TYRO3 and phosphoinositide 3-kinase/protein B kinase/mammalian target of rapamycin pathway suppression.
Qin A; Qian W
Int J Mol Med; 2018 Nov; 42(5):2503-2514. PubMed ID: 30226533
[TBL] [Abstract][Full Text] [Related]
4. Long noncoding RNA ABHD11-AS1 predicts the prognosis of pancreatic cancer patients and serves as a promoter by activating the PI3K-AKT pathway.
Qiao X; Lv SX; Qiao Y; Li QP; Ye B; Wang CC; Miao L
Eur Rev Med Pharmacol Sci; 2018 Dec; 22(24):8630-8639. PubMed ID: 30575903
[TBL] [Abstract][Full Text] [Related]
5.
Saito T; Itoh M; Tohda S
Anticancer Res; 2022 Apr; 42(4):1757-1761. PubMed ID: 35346994
[TBL] [Abstract][Full Text] [Related]
6. Tyro3-mediated phosphorylation of ACTN4 at tyrosines is FAK-dependent and decreases susceptibility to cleavage by m-Calpain.
Shao H; Wang A; Lauffenburger D; Wells A
Int J Biochem Cell Biol; 2018 Feb; 95():73-84. PubMed ID: 29274473
[TBL] [Abstract][Full Text] [Related]
7. Reduced kinase D‑interacting substrate of 220 kDa (Kidins220) in pancreatic cancer promotes EGFR/ERK signalling and disease progression.
Cai S; Sun Z; Sun PH; Gao X; Ji K; Tian X; Ji J; Hao C; Soliman F; Liu C; Al-Sarireh B; Griffiths P; Hiscox S; Jiang WG; Ye L
Int J Oncol; 2021 Jun; 58(6):. PubMed ID: 33955519
[TBL] [Abstract][Full Text] [Related]
8. Targeting the Janus-activated kinase-2-STAT3 signalling pathway in pancreatic cancer using the HSP90 inhibitor ganetespib.
Nagaraju GP; Mezina A; Shaib WL; Landry J; El-Rayes BF
Eur J Cancer; 2016 Jan; 52():109-19. PubMed ID: 26682870
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of Tyro3 expression, Gas6-mediated Akt phosphorylation, and the impact of anti-Tyro3 antibodies in melanoma cell lines.
Demarest SJ; Gardner J; Vendel MC; Ailor E; Szak S; Huang F; Doern A; Tan X; Yang W; Grueneberg DA; Richards EJ; Endege WO; Harlow E; Koopman LA
Biochemistry; 2013 May; 52(18):3102-18. PubMed ID: 23570341
[TBL] [Abstract][Full Text] [Related]
10. High mobility group AT-hook 1 (HMGA1) is an independent prognostic factor and novel therapeutic target in pancreatic adenocarcinoma.
Liau SS; Rocha F; Matros E; Redston M; Whang E
Cancer; 2008 Jul; 113(2):302-14. PubMed ID: 18473350
[TBL] [Abstract][Full Text] [Related]
11. CD110 promotes pancreatic cancer progression and its expression is correlated with poor prognosis.
Yan Z; Ohuchida K; Zheng B; Okumura T; Takesue S; Nakayama H; Iwamoto C; Shindo K; Moriyama T; Nakata K; Miyasaka Y; Ohtsuka T; Mizumoto K; Oda Y; Hashizume M; Nakamura M
J Cancer Res Clin Oncol; 2019 May; 145(5):1147-1164. PubMed ID: 30770989
[TBL] [Abstract][Full Text] [Related]
12. The catalytically defective receptor protein tyrosine kinase EphA10 promotes tumorigenesis in pancreatic cancer cells.
Shin WS; Park MK; Lee YH; Kim KW; Lee H; Lee ST
Cancer Sci; 2020 Sep; 111(9):3292-3302. PubMed ID: 32644283
[TBL] [Abstract][Full Text] [Related]
13. Insulin-like growth factor 2 mRNA-binding protein 1 promotes cell proliferation
Wan BS; Cheng M; Zhang L
World J Gastroenterol; 2019 Oct; 25(40):6063-6076. PubMed ID: 31686763
[TBL] [Abstract][Full Text] [Related]
14. EG-VEGF silencing inhibits cell proliferation and promotes cell apoptosis in pancreatic carcinoma via PI3K/AKT/mTOR signaling pathway.
Yan X; Hui Y; Hua Y; Huang L; Wang L; Peng F; Tang C; Liu D; Song J; Wang F
Biomed Pharmacother; 2019 Jan; 109():762-769. PubMed ID: 30551529
[TBL] [Abstract][Full Text] [Related]
15. High Novel Oncogene with Kinase-Domain (NOK) Gene Expression is Associated with the Progression of Renal Cell Carcinoma.
Cao Q; Chen M; Li Z; Huang W; Jin Y; Ye X; Tong M
Clin Lab; 2016; 62(1-2):179-86. PubMed ID: 27012048
[TBL] [Abstract][Full Text] [Related]
16. TSPAN1 upregulates MMP2 to promote pancreatic cancer cell migration and invasion via PLCγ.
Zhang X; Shi G; Gao F; Liu P; Wang H; Tan X
Oncol Rep; 2019 Apr; 41(4):2117-2125. PubMed ID: 30720116
[TBL] [Abstract][Full Text] [Related]
17. TYRO3 as a molecular target for growth inhibition and apoptosis induction in bladder cancer.
Dufour F; Silina L; Neyret-Kahn H; Moreno-Vega A; Krucker C; Karboul N; Dorland-Galliot M; Maillé P; Chapeaublanc E; Allory Y; Stransky N; Haegel H; Menguy T; Duong V; Radvanyi F; Bernard-Pierrot I
Br J Cancer; 2019 Mar; 120(5):555-564. PubMed ID: 30765874
[TBL] [Abstract][Full Text] [Related]
18. The stem cell factor/c-kit receptor pathway enhances proliferation and invasion of pancreatic cancer cells.
Yasuda A; Sawai H; Takahashi H; Ochi N; Matsuo Y; Funahashi H; Sato M; Okada Y; Takeyama H; Manabe T
Mol Cancer; 2006 Oct; 5():46. PubMed ID: 17044945
[TBL] [Abstract][Full Text] [Related]
19. STYK1 promotes epithelial-mesenchymal transition and tumor metastasis in human hepatocellular carcinoma through MEK/ERK and PI3K/AKT signaling.
Wang Z; Qu L; Deng B; Sun X; Wu S; Liao J; Fan J; Peng Z
Sci Rep; 2016 Sep; 6():33205. PubMed ID: 27628214
[TBL] [Abstract][Full Text] [Related]
20. The clinicopathological significance and relationship of Gli1, MDM2 and p53 expression in resectable pancreatic cancer.
Sheng W; Dong M; Zhou J; Li X; Liu Q; Dong Q; Li F
Histopathology; 2014 Mar; 64(4):523-35. PubMed ID: 24289472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
